Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property protections in the U.S. and Japan, marking a pivotal step in Lantern Pharma's global commercialization strategy for LP-284.

Developed using Lantern’s innovative RADR(R) AI platform, LP-284 is currently undergoing Phase 1 clinical trials and has been granted Orphan Drug Designations for Mantle Cell Lymphoma (MCL) and High-Grade B-Cell Lymphoma (HGBL). The drug is targeting a substantial global market estimated at $4 billion. The rapid development timeline and cost efficiency of LP-284, facilitated by Lantern’s AI-driven approach, significantly enhance the drug's appeal for strategic partnerships and further development.

The RADR(R) platform, a cornerstone of Lantern Pharma's drug discovery and development process, utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms. This powerful combination has enabled Lantern to accelerate the development of its oncology drug pipeline, reducing the time from initial AI insights to first-in-human clinical trials to just 2-3 years, with an average cost of approximately $2.5 million per program.

This latest patent approval not only strengthens Lantern Pharma's intellectual property portfolio but also underscores the potential of AI in revolutionizing the oncology drug development landscape. By leveraging cutting-edge technology, Lantern Pharma is setting new standards for efficiency and innovation in the fight against cancer, offering hope to patients with limited treatment options.